Global Non-Invasive Prenatal Testing (NIPT) Market 2020-2031: Focus on Method, Test, Platform, End-user, Application and Country - ResearchAndMarkets.com | Business Wire
AUSTIN, Texas and SHENZHEN, China, June 24, 2021 /PRNewswire/ - Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, and BGI Genomics Co., Ltd., (300676.SZ), one of the world's leading genomics companies, today announced the launch of the BGI/Natera Signatera Assay which is now available to biopharmaceutical customers and clinicians across China.
China's top gene-sequencing provider BGI will participate in the Genome Program, which aims to use genomic data to improve health outcomes in the United Arab Emirates (UAE), the company announced Wednesday.
"An attractive and dynamic business climate for high value-added products - indeed, that is what we see in Latvia." BGI, one of the world's largest genomics organizations, is a striking example of how LIAA attracts foreign investment and successful companies to Latvia.
NEW YORK - Building on an earlier licensing partnership, BGI Genomics and Natera have launched a clinical research program to use Signatera in China for colorectal cancer patients.
Natera and BGI Genomics Announce $50M Partnership to Commercialize Signatera Oncology Test in China and to Develop Reproductive Health Tests in Select Markets on BGI's DNBseq™ Technology Platform | Natera
NEW YORK - Chinese diagnostics firm BGI Genomics reported last week that its H1 2021 revenues declined 11 percent due to decreasing demand for COVID-19 testing.
If you're looking for a new fragrance that can transform your personality, then you must try Colour Me Black perfume. This captivating fragrance has been designed to evoke a sense of sensuality and confidence, and is perfect for those who want to make a bold statement. With its unique blend of exotic and alluring notes, Colour Me Black is a perfume that is sure to turn heads.
Group items tagged 
